JNJ 63709178

Drug Profile

JNJ 63709178

Alternative Names: CD123 x CD3 DuoBody; CD123-CD3 DuoBody protein; CNTO 9958; JNJ-63709178

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab; Janssen Research & Development
  • Developer Janssen Research & Development
  • Class Bispecific antibodies
  • Mechanism of Action CD3 antigen modulators; Interleukin 3 receptor alpha subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 01 Jun 2018 Janssen Research & Development suspended a phase I trial due to Grade 3 events for Acute myeloid leukaemia (Second-line therapy or greater) in USA and Spain (IV) (NCT02715011)
  • 05 Apr 2017 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT02715011)
  • 16 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top